Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development
Allarity Therapeutics provided an update on its Drug Response Predictor (DRP) technology, recent patent awards, and CLIA certification of its in-house lab, which the company says solidify commercial exclusivity of stenoparib. At AACR 2026, an exploratory analysis of a prior Phase 2 ovarian cancer cohort showed higher pretreatment DRP scores were associated with longer overall survival on twice-daily stenoparib. The company plans to use DRP-guided patient selection for a potential pivotal trial as stenoparib advances toward FDA approval, and sees external diagnostic partnership opportunities.
Key figures
- Drug Name
- stenoparib (2X-121, formerly E7449)
- Phase Of Trial
- Phase 2
- Drp gene signature
- 414-gene expression signature
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.